Nicotinamide Riboside Ameliorates Hepatic Metaflammation by Modulating NLRP3 Inflammasome in a Rodent Model of Type 2 Diabetes

Journal of Medicinal Food

Volumn 18, Issue 11, 2015, Pages 1207-1213

  Lee, Hee Jae ^a   Hong, Young Shick ^a   Jun, Woojin ^a   Yang, Soo Jin ^b  

^a Chonnam National University   (South Korea)

^b Seoul Women University   (South Korea)

Author keywords

Hepatic metaflammation; Nicotinamide riboside; NLRP3 inflammasome

Indexed keywords

ADIPONECTIN; CHOLESTEROL; CRYOPYRIN; INFLAMMASOME; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; NICOTINAMIDE RIBOSIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NICOTINAMIDE; NICOTINAMIDE-BETA-RIBOSIDE; PYCARD PROTEIN, MOUSE; VITAMIN B COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; FOOD INTAKE; HEPATIC METAFLAMMATION; HEPATITIS; HISTOLOGY; INSULIN BLOOD LEVEL; LIVER FUNCTION; MALE; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INFLAMMATION; LIVER; METABOLISM; MOUSE; PATHOLOGY;

ADIPONECTIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS REGULATORY PROTEINS; BLOOD GLUCOSE; CARRIER PROTEINS; CASPASE 1; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; INFLAMMASOMES; INFLAMMATION; INSULIN; INTERLEUKIN-1BETA; LIVER; MALE; MICE; NIACINAMIDE; OBESITY; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN B COMPLEX;

EID: 84946070221     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.3439     Document Type: Article

References (40)

1. Bieganowski P, Brenner C: Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss- Handler independent route to NAD+ in fungi and humans. Cell 2004;117:495-502.
2. Belenky P, Bogan KL, Brenner C: NAD+ metabolism in health and disease. Trends Biochem Sci 2007;32:12-19.
3. Imai S, Guarente L: NAD+ and sirtuins in aging and disease. Trends Cell Biol 2014;24:464-471.
4. Giblin W, Skinner ME, Lombard DB: Sirtuins: Guardians of mammalian healthspan. Trends Genet 2014;30:271-286.
5. Klaidman L, Morales M, Kem S, et al.: Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+ , as a PARP inhibitor and by partial restoration of mitochondrial function. Pharmacology 2003;69:150-157.
6. Knip M1, Douek IF, Moore WP, et al.: Safety of high-dose nicotinamide: A review. Diabetologia 2000;43:1337-1345.
7. Yang T, Chan NY, Sauve AA: Syntheses of nicotinamide riboside and derivatives: Effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J Med Chem 2007;50:6458-6461.
8. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
9. Fabbrini E, Magkos F, Mohammed BS, et al.: Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:15430-15435.
10. Martinon F, Burns K, Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-426.
11. NeteaMG, van der Meer JW: Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med 2011;364:60-70.
12. Takeuchi O, Akira S: Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
13. Szabo G, Csak T: Inflammasomes in liver diseases. J Hepatol 2012;57:642-654.
14. Wen H, Ting JP, O'Neill LA: A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol 2012;13:352-357.
15. Wree A, Eguchi A, McGeough MD, et al.: NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014;59:898-910.
16. Wree A, McGeough MD, Pena CA, et al.: NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med 2014;92:1069-1082.
17. Canto C, Houtkooper RH, Pirinen E, et al.: The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012; 15:838-847.
18. Khan NA, Auranen M, Paetau I, et al.: Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med 2014;6:721-731.
19. Cerutti R, Pirinen E, Lamperti C, et al.: NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 2014;19:1042-1049.
20. Gong B, Pan Y, Vempati P, et al.: Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptorgamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 2013;34:1581-1588.
21. Guyton JR, Bays HE: Safety considerations with niacin therapy. Am J Cardiol 2007;99:22c-31c.
22. Ganji SH, Kamanna VS, Kashyap ML: Niacin and cholesterol: Role in cardiovascular disease (review). J Nutr Biochem 2003; 14:298-305.
23. Altschul R, Hoffer A, Stephen JD: Influence of nicotinic acid on serumcholesterol inman. Arch BiochemBiophys 1955;54:558-559.
24. Meyers CD, Kamanna VS, Kashyap ML: Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004;15:659-665.
25. Ganji SH, Tavintharan S, Zhu D, et al.: Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-1845.
26. Stone SJ, Myers HM, Watkins SM, et al.: Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 2004;279:11767-11776.
27. Kadowaki T, Yamauchi T, Kubota N, et al.: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-1792.
28. Blüher M: Clinical relevance of adipokines. Diabetes Metab J 2012;36:317-327.
29. George J, Patal S, Wexler D, et al.: Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006;92:1420-1424.
30. Martinez Cantarin MP, Keith SW, Deloach S, Huan Y, Falkner B: Relationship of adipokines with insulin sensitivity in African Americans. Am J Med Sci 2011;342:192-197.
31. Maeda N, Takahashi M, Funahashi T, et al.: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099.
32. Li S, Shin HJ, Ding EL, van Dam RM: Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2009;302:179-188.
33. Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
34. Bryant C, Fitzgerald KA: Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 2009;19:455-464.
35. Pedra JH, Cassel SL, Sutterwala FS: Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009; 21:10-16.
36. Vandanmagsar B, Youm YH, Ravussin A, et al.: The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179-188.
37. Masters SL, Dunne A, Subramanian SL, et al.: Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010;11:897-904.
38. Duewell P, Kono H, Rayner KJ, et al.: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-1361.
39. Dostert C, Ludigs K, Guarda G: Innate and adaptive effects of inflammasomes on T cell responses. Curr Opin Immunol 2013; 25:359-365.
40. Goossens GH, Blaak EE, Theunissen R, et al.: Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol 2012;50:142-149.